|
業務類別
|
Biotechnology |
|
業務概覽
|
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases. |
| 公司地址
| 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609 |
| 電話號碼
| +1 919 659-5677 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.vogenx.com |
| 員工數量
| 5 |
| Mr. Steven R. Delmar |
Director, Corporate Secretary and Chief Financial Officer |
-- |
29/07/2026 |
| Mr. James Green |
Chairman of the Board, President and Chief Executive Officer |
-- |
29/07/2026 |
| Dr. William Wilkison, PhD |
Director and Chief Scientific Officer |
-- |
29/07/2026 |
| Mr. Richard Gorman |
Chief Commercial Officer |
-- |
09/10/2026 |
|
|
| Mr. Steven R. Delmar |
Director, Corporate Secretary and Chief Financial Officer |
29/07/2026 |
| Mr. Timothy Boris |
Independent Director |
29/07/2026 |
| Mr. James Green |
Chairman of the Board, President and Chief Executive Officer |
29/07/2026 |
| Dr. William Wilkison, PhD |
Director and Chief Scientific Officer |
29/07/2026 |
| Mr. Peter Pieraccini |
Independent Director |
29/07/2026 |
| Mr. Kenneth John Toombs |
Independent Director |
22/09/2026 |
|
|
|
|